Acceleron Pharma Initiates Phase 2 Clinical Trial to Evaluate Long-Term Effects of ACE-083 in Patients with Charcot-Marie Tooth (CMT) Disease

This new ACE-083 study was added to ClinicalTrials.gov on May 9, 2019 and is now enrolling patients with CMT1 and CMTX across the United States, Canada, and Spain.

The FDA granted Fast Track designation to ACE-083, Acceleron Pharma’s “locally-acting ‘Myostatin+’ muscle agent” for the treatment of Charcot-Marie-Tooth disease (CMT), back in November 2018. See this press release for full background story.

Acceleron Pharma continues to move ACE-083 forward, as planned, with this newest study.

STUDY LINK: https://clinicaltrials.gov/ct2/show/study/NCT03943290